// App-Quantinova.ai

850 : Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

Researchers

Presenter

  • Ruth Plummer

Principal Investigators

  • Brid Ryan

  • Ilian Tachkov

  • Vikash Reebye

  • Tim Meyer

  • David Pinato

  • Debashis Sarker

  • Bristi Basu

  • Sarah Blagden

  • Natalie Cook

  • Jeff Evans

  • Jeffrey Yachnin

  • Cheng-Ean Chee

  • Daneng Li

  • Anthony El-Khoueiry

  • Maria Diab

  • Kai-Wen Huang

  • Antonio D'Alessio

  • Claudia Fulgenzi

  • Marcus Noel

  • Bridget Keenan

  • Devalingam Mahalingam

  • Nina Raulf

  • Rose Hogson

  • Choon Ping Tan

  • Joanna Nicholls

  • Alison Adderkin

  • Julia Vassiliadou

  • Robert Habib

  • John Rossi

  • Nagy Habib

Medical Centers

  • University College London, London, UK

  • OCDEM, University of Oxford, Oxford, UK

  • EScience, University of Glasgow, Glasgow, UK

  • MedStar Georgetown University Hospital Washington DC United States

  • University of California, San Francisco, San Francisco, CA

  • University of Southern California, Los Angeles, CA

  • City of Hope Comprehensive Cancer Center,Duarte, CA,États-unis

  • University of Cambridge, Cambridge, UK

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Emory University, Atlanta, Georgia, United States

  • Karolinska University Hospital, Stockholm, Sweden

  • Newcastle University, Newcastle Upon Tyne, UK

  • National Taiwan University Hospital, Taipei City, Taiwan

  • MiNA Therapeutics Ltd, London, UK

  • Beckman Research institute, City of Hope, Duarte, California, United States

  • National University Cancer Institute of Singapore, Singapore, Singapore

  • Global Health, Northwestern University, Chicago, IL, United States

Locations

  • United Kingdom

  • United States

  • Sweden

  • Taiwan

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • MTL-CEBPA

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT-04105335

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved